Investment Q&A

Q: Please provide your views and commentary on Emerson Electric (EMR). I'm thinking it likely has good opportunities in respect of anticipated increases in infrastructure spending in the US.

Q: Why the big drop in price today?

Q: Dear 5i team.

I'm considering adding to my IHAK position but wanted to clear up something with you first.
In the archives, you mentioned that a combination of CRWD/NET/PANW would be an alternative to owning the ETFs IHAK or HACK. Are you still of this view? Do you still prefer IHAK to HACK?
Are the valuations of these holdings back to a level that reflects current realities?

Many thanks for your help.

Q: Cybersecurity companies have been weak. I have BUG and am thinking of adding. I'm also considering CRWD. Should I consider the timing premature in view of the downtrend, or is there a screaming buy here?
John

Q: Does your view on Broadcom change with the announcement of Apple plans to take back some of the manufacturing done by AVGO? Is AVGO a stock worth holding or are there others to consider with less risk?

Q: This stock is headed for bankruptcy it seems. Why is the stock rallying in a big way. Shouldnt the shares be trickling down to NIL as the current shares are likely to be worthless?

Q: We often see conflicting analyst opinions, but ratings of MDT seem to be on one extreme or other. For what it’s worth, MDT appears on various lists of “best stocks for 2023”. And just this week, Barrons carried this story: “ Buy Medtronic Stock. Shares of the Dividend Aristocrat Look Attractive” (January 2). This morning RBC-DI downgraded MDT from outperform while CFRA maintains a Buy. Both RBC-DI and CFRA seem to reasonably good track records. I have held MDT shares from multi-year highs all the way down to today’s miserable level. (Tax loss not useable).

I have previously asked you about MDT and possibly others here may have done so too. Would you care to take a side in this frustrating debate with your reasons? Thanks.

Q: Could you provide any information/prospects on the above stock? Thanks.

Q: Asked by Doris on January 09, 2023
5I RESEARCH ANSWER:
We are not big fans of the staples sector overall right now in the US. It has fared decently over the last year but valuations are at the higher end now, as growth should moderate alongside inflation. Also, now that bonds offer more attractive yields, we think the relative attractiveness of staples is lower than it was a year ago (more safe alternatives for stability and yield now).

We think it is difficult to be too hard on COST though. Overall, we think staples names in Canada look a bit more attractive due to what looks like lower valuations on average. In Canada, we think PBH, ATD and NWC are worth looking at.

this is an answer you gave regarding staples . would you feel the same eay about hwalthcare stocks, such as gilead, etc

Q: what is your feeling on Medtronic now? If I buy it in a US RRSP is there still a whitholding tax?

Q: Both have had a good run but I just own Starbucks. I'm considering swapping it for TJX. What do you think?

Q: What is going on with Enphase stock? It has gone almost straight down since mid-december. It's last quarter looked quite good. Is it worries over the next quarter?

Q: I'm wondering about the big drop in JNJ today?

Q: It's time to add to my TFSA. I own ADBE, GOOG, AAPL, NVDA, PYPL, QCOM, CRM and TOL in this account, where longterm growth is the investment objective. Should any of these be switched? Please recommend replacements if so and ignore sector/market cap considerations. I wish to add to either NVDA or PYPL, which of these should I add to? Deduct as many credits as required. Thanks, and wishing you all the best for 2023.

Q: Peter; Does the Broadcom deal impact other chip companies, like NVDA? Is it a “ big”: deal in the chip market? Thanks
Rod

Q: I'm looking at your answer to Shane's Jan 5 question about your caveats on recovery of stocks. Do you see any of the stocks listed here whose recovery may be limited and if so, which ones and based on which caveats? Thank you.

Q: I thought that I had asked this question before, but I went through 6 web pages of "My Questions" and came up empty.

What would you say is the "most" CSU-like stock in the US? Thanks again!

Q: I just wanted to circle back to one of my last questions around META to confirm something. I had a typo in my question where I said $425M shares but had the dollar sign accidentally, making it seem like the buyback was $425M dollars in shares, but in fact its 425M shares, which is obviously WAY more of a spend. You mentioned that there would be no dilution since their recent buybacks outweigh the new share increase. But with the correction mentioned above I believe it would put the 2023 share count a fair bit higher than the 2022 and 2021, which hasn't happened for a number of years for FB since they've been lowering the share count since 2018. Does this add up, and is META in fact diluting a fair bit with this move? Thx. I see 2020: 2,851B
2021: 2,815B
2022: Not sure
2023: With addition of 425M shares, somewhere above 3B

Q: I'm wanting to increase my holdings in US healthcare. For share price appreciation and safety, which would you prefer and why?

Q: Hi,
Of this list do any of these names have concerns and if so, what might they be? Are there any you would wish to wait longer before buying? Any you do not think appropriate buys in this market? Others you feel are more compelling? If you were to buy these, in what order would you do so? I know - lots of questions - feel free to deduct accordingly! My preference is for stability of future earnings, lower or no debt and the dividend is a bit of a bonus, but not something to rely on. Many thanks!
Dawn